Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) - Drugs In Development, 2021

July 2021 | 415 pages | ID: KF1765A19881EN
Global Markets Direct

Abstracts

Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca - Drugs In Development, 2021, provides an overview of the Keratoconjunctivitis Sicca (Ophthalmology) pipeline landscape.

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 19, 37, 14, 2, 43, 8 and 8 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.

Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Keratoconjunctivitis Sicca (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Keratoconjunctivitis Sicca (Dry Eye) - Overview
Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Development
Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Assessment
Keratoconjunctivitis Sicca (Dry Eye) - Companies Involved in Therapeutics Development
Keratoconjunctivitis Sicca (Dry Eye) - Drug Profiles
Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects
Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products
Keratoconjunctivitis Sicca (Dry Eye) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by AB2 Bio Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by AbbVie Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Abilita Bio Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Actinobac Biomed Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aerie Pharmaceuticals Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allegro Ophthalmics LLC, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allgenesis Biotherapeutics Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allosterix Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allysta Pharmaceuticals Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Apidel SA, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aviara Pharmaceuticals Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Avixgen Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by AxeroVision Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Azura Ophthalmics Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Beijing Northland Biotech Co Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Bessor Pharma LLC, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by BRIM Biotechnology Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Cambium Medical Technologies LLC, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Cellix Bio Pvt Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Cloudbreak Therapeutics LLC, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Dhp Korea Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Dompe Farmaceutici SpA, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Evergreen Therapeutics Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by EyeGate Pharmaceuticals Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by GL Pharm Tech Corp, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Glaukos Corp, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Glia LLC, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by HanAll Biopharma Co Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Huons Co Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Huons Global Co Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by IACTA Pharmaceuticals Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Icure Pharmaceutical Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Ildong Pharmaceutical Co Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Intratus Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Ipsen SA, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by IVIEW Therapeutics Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Japan Tobacco Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Juvenescence UK Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals Inc, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Kowa Co Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Kv1.3 Therapeutics, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Laboratoires Thea SA, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Laboratorios Sophia SA de CV, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects, 2021
Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021